BR9710560A - Composi-Æo farmac-utica antitrombÄtica e antiaterogenica que compreende um derivado de tienopiridina e um inibidor da hmg-coa-redutase - Google Patents

Composi-Æo farmac-utica antitrombÄtica e antiaterogenica que compreende um derivado de tienopiridina e um inibidor da hmg-coa-redutase

Info

Publication number
BR9710560A
BR9710560A BR9710560A BR9710560A BR9710560A BR 9710560 A BR9710560 A BR 9710560A BR 9710560 A BR9710560 A BR 9710560A BR 9710560 A BR9710560 A BR 9710560A BR 9710560 A BR9710560 A BR 9710560A
Authority
BR
Brazil
Prior art keywords
atherogenic
antithrombotic
hmg
pharmaceutical composition
reductase inhibitor
Prior art date
Application number
BR9710560A
Other languages
English (en)
Other versions
BR9710560B1 (pt
Inventor
Georges Daste
Jean-Marc Herbert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR9710560A publication Critical patent/BR9710560A/pt
Publication of BR9710560B1 publication Critical patent/BR9710560B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
    • F16K41/00—Spindle sealings
    • F16K41/02—Spindle sealings with stuffing-box ; Sealing rings
    • F16K41/04—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing
    • F16K41/043—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles
    • F16K41/046—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles for rotating valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02D—CONTROLLING COMBUSTION ENGINES
    • F02D9/00—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits
    • F02D9/04—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits concerning exhaust conduits
    • F02D9/06—Exhaust brakes
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
    • F16K1/00—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces
    • F16K1/16—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members
    • F16K1/18—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps
    • F16K1/22—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps with axis of rotation crossing the valve member, e.g. butterfly valves

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Combustion & Propulsion (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI9710560-0B1A 1996-07-26 1997-07-21 Composição farmacêutica contendo clopidogrel e sinvastatina, bem como seus usos. BR9710560B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609474A FR2751540B1 (fr) 1996-07-26 1996-07-26 Composition pharmaceutique antithrombotique
PCT/FR1997/001353 WO1998004259A1 (fr) 1996-07-26 1997-07-21 COMPOSITION PHARMACEUTIQUE ANTITHROMBOTIQUE ET ANTIATHEROGENE COMPRENANT UN DERIVE DE THIENOPYRIDINE ET UN INHIBITEUR DE LA HMG-CoA-REDUCTASE

Publications (2)

Publication Number Publication Date
BR9710560A true BR9710560A (pt) 1999-08-17
BR9710560B1 BR9710560B1 (pt) 2013-12-03

Family

ID=9494551

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9710560-0B1A BR9710560B1 (pt) 1996-07-26 1997-07-21 Composição farmacêutica contendo clopidogrel e sinvastatina, bem como seus usos.

Country Status (34)

Country Link
US (1) US6218403B1 (pt)
EP (1) EP0914124B1 (pt)
JP (1) JP3553610B2 (pt)
KR (1) KR100307268B1 (pt)
CN (1) CN1109547C (pt)
AR (1) AR008782A1 (pt)
AT (1) ATE258052T1 (pt)
AU (1) AU725949B2 (pt)
BR (1) BR9710560B1 (pt)
CA (1) CA2261099C (pt)
CZ (1) CZ294664B6 (pt)
DE (1) DE69727299T2 (pt)
DK (1) DK0914124T3 (pt)
EE (1) EE03853B1 (pt)
ES (1) ES2214632T3 (pt)
FR (1) FR2751540B1 (pt)
HU (1) HU226245B1 (pt)
ID (1) ID17774A (pt)
IL (1) IL128102A0 (pt)
IS (1) IS2052B (pt)
MY (1) MY125051A (pt)
NO (1) NO322894B1 (pt)
NZ (1) NZ333826A (pt)
PL (1) PL188739B1 (pt)
PT (1) PT914124E (pt)
RS (1) RS49504B (pt)
RU (1) RU2176504C2 (pt)
SI (1) SI0914124T1 (pt)
SK (1) SK284944B6 (pt)
TR (1) TR199900154T2 (pt)
TW (1) TW442289B (pt)
UA (1) UA58518C2 (pt)
WO (1) WO1998004259A1 (pt)
ZA (1) ZA976247B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
CA2470479A1 (en) * 2001-12-18 2003-06-26 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
DE602004029362D1 (de) * 2003-06-18 2010-11-11 Inst Cardiologie De Montreal M Vermeidung von vorhofflimmern (af) mit der verwendung von statin
US6978908B2 (en) * 2003-09-15 2005-12-27 Gerber Products Company Drinking vessel with adjustable handles
RU2261705C1 (ru) * 2004-01-29 2005-10-10 Медведев Илья Николаевич Способ лечения тромбоцитопатии при метаболическом синдроме
KR100563455B1 (ko) * 2004-04-09 2006-03-23 한미약품 주식회사 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
SG165379A1 (en) * 2005-09-15 2010-10-28 Otsuka Pharma Co Ltd Combination drug containing probucol and a tetrazolylalkoxy- dihydrocarbostyril derivative with superoxide supressant effects
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
HUE040311T2 (hu) * 2006-04-04 2019-02-28 Kg Acquisition Llc Vérlemezke aggregációt gátló szert és sav inhibitort tartalmazó orális dózisformák
EP1931682A2 (en) * 2006-08-03 2008-06-18 Teva Pharmaceutical Industries Ltd. Process for preparing clopidogrel bisulphate
WO2008060934A2 (en) * 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
EP2155168A2 (en) * 2007-04-09 2010-02-24 USV Limited Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
EP2148655B1 (en) * 2007-04-20 2013-02-27 Wockhardt Limited Pharmaceutical compositions of clopidogrel
US8343995B2 (en) * 2007-04-27 2013-01-01 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP2303233B1 (en) * 2008-07-25 2012-06-20 Pharmathen S.A. Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
RU2396079C1 (ru) * 2008-12-03 2010-08-10 Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) (статус государственного учреждения) Лекарственное средство с гиполипидемическим эффектом "аторваглизин"
EA021588B1 (ru) 2009-06-25 2015-07-30 Тетра Сиа Бетаиновые соли ацетилсалициловой кислоты
JP2020507621A (ja) 2017-01-23 2020-03-12 ドン ファ ファーマシューティカル カンパニー リミテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤およびクロピドグレルを含む複合製剤
CN118185711A (zh) * 2024-02-28 2024-06-14 湖北兴福电子材料股份有限公司 一种铜钴钨兼容性好的TiN去除组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
WO1995011898A1 (en) * 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke

Also Published As

Publication number Publication date
RU2176504C2 (ru) 2001-12-10
AU725949B2 (en) 2000-10-26
ATE258052T1 (de) 2004-02-15
CN1109547C (zh) 2003-05-28
NO322894B1 (no) 2006-12-18
NZ333826A (en) 2000-09-29
CA2261099A1 (fr) 1998-02-05
PT914124E (pt) 2004-05-31
PL188739B1 (pl) 2005-04-29
HU226245B1 (en) 2008-07-28
MY125051A (en) 2006-07-31
BR9710560B1 (pt) 2013-12-03
TW442289B (en) 2001-06-23
SI0914124T1 (en) 2004-06-30
SK7899A3 (en) 1999-07-12
PL331339A1 (en) 1999-07-05
IL128102A0 (en) 1999-11-30
IS4951A (is) 1999-01-22
FR2751540A1 (fr) 1998-01-30
CN1228698A (zh) 1999-09-15
NO990321D0 (no) 1999-01-25
KR100307268B1 (ko) 2001-09-24
YU3199A (sh) 2002-09-19
CA2261099C (fr) 2003-04-15
EE03853B1 (et) 2002-10-15
UA58518C2 (uk) 2003-08-15
FR2751540B1 (fr) 1998-10-16
JP3553610B2 (ja) 2004-08-11
HUP9903752A2 (hu) 2000-03-28
SK284944B6 (sk) 2006-03-02
US6218403B1 (en) 2001-04-17
HUP9903752A3 (en) 2001-12-28
EE9900028A (et) 1999-08-16
AU3852697A (en) 1998-02-20
CZ294664B6 (cs) 2005-02-16
ZA976247B (en) 1999-01-15
AR008782A1 (es) 2000-02-23
WO1998004259A1 (fr) 1998-02-05
JP2000500781A (ja) 2000-01-25
CZ17699A3 (cs) 1999-05-12
EP0914124A1 (fr) 1999-05-12
NO990321L (no) 1999-03-22
DE69727299D1 (de) 2004-02-26
TR199900154T2 (xx) 1999-04-21
RS49504B (sr) 2006-10-27
IS2052B (is) 2005-10-14
DE69727299T2 (de) 2004-10-21
ID17774A (id) 1998-01-29
ES2214632T3 (es) 2004-09-16
HK1019405A1 (en) 2000-02-11
EP0914124B1 (fr) 2004-01-21
DK0914124T3 (da) 2004-05-17
KR20000029484A (ko) 2000-05-25

Similar Documents

Publication Publication Date Title
PT914124E (pt) Composicao farmaceutica anti-trombotica e anti-aterogenica compreendendo um derivado de tienopiridina e um inibidor da hmg-coa-reductase
NZ305254A (en) Farnesyl protein inhibitors and pharmaceutical compositions thereof
IL122485A0 (en) Arylsulfonylaminobenzene derivatives and pharmaceutical compositions containg the same
PT978276E (pt) Comprimidos com revestimento de polimero que compreendem amoxicilina e clavulanato
FI964028L (fi) Uusi farmaseuttinen formulaatio ja menetelmä
NO20021172L (no) Farmasöytisk sammensetning
EP0865788A4 (en) FOR CYCLOOXYGENASE 2 SPECIFIC INHIBITOR AND ANTI-INFLAMMATORY SUBSTANCE
ZA965750B (en) Farnesyl transferase inhibitors their preparation and pharmaceutical composition comprising them
DE69622735D1 (de) Lyophilisierte stabile pharmazeutische formulierung
EE04091B1 (et) Koostised ja meetodid silmasisese rõhu alandamiseks
FI955144A0 (fi) Päällystetyt farmaseuttiset koostumukset
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
EP0729354A4 (en) FARNESYL DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM
DK0907364T3 (da) Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat
PT956294E (pt) Inibidores da trombina
PT948483E (pt) Inibidores da farnesil-transferase
BR9709947A (pt) Novo derivado tiofeno e composição farmacêutica do mesmo
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
HUP9602196A2 (en) Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
LV11727A (lv) Farmaceitiska kompozicija
FI973280A7 (fi) Farmaseuttinen koostumus
BR9609723A (pt) Derivados da tricetona
BR9605777A (pt) Composição farmacêutica
HUP0001524A3 (en) Covalent phospholipid-phosphono-carboxylic acid conjugates and pharmaceutical compositions thereof
AU1195597A (en) Dibenzothiepin derivatives and pharmaceutical compositions

Legal Events

Date Code Title Description
PC Transfer

Free format text: SANOFI-SYNTHELABO (FR)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE A MATERIA REIVINDICADA NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA, DE ACORDO COM ART. 13 DA LPI, NAO SENDO PASSIVEL DE PROTECAO SEGUNDO O ART. 8O DA MESMA LEI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.